logo-loader
viewImmuPharma PLC

Interim Results Announcement

/**/ sup{font-size:80%}h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;text-decoration:underline;}p{margin-right:0cm;margin-left:6.45pt;font-size:10.0pt;font-family:"Verdana","sans-serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .aq{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 72.0pt 90.0pt;}div.aq{}p.nr{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;text-align: left}p.ns{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold}span.no{color:black}p.nt{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: center}p.nu{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; text-align: center}p.nv{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";background:white}p.nw{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-decoration: underline}p.nx{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:35.45pt;text-indent:-14.15pt; background:white} span.ni{font-size:10.0pt;line-height:107%;font-family: Symbol;color:black}span.nh{font-size:10.0pt;line-height:107%; font-family:"Times New Roman","serif";color:black}p.ny{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:49.65pt;text-indent: -14.2pt;background:white}span.nf{font-size:10.0pt;line-height:107%; font-family:"Courier New";color:black}span.ne{font-size:10.0pt; line-height:107%;font-family:"Times New Roman","serif";color:black}p.nz{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:49.65pt;text-indent: -14.2pt}span.nc{font-size:10.0pt;line-height:107%;font-family:"Courier New"; color:black}span.na{font-size:10.0pt; line-height:107%;font-family:"Times New Roman","serif"}p.oa{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:78.0pt;text-indent:-14.2pt; background:white}span.mz{font-size:10.0pt;line-height:107%;font-family: Wingdings;color:black} p.ob{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:126.0pt;background:white}span.mx{font-size:10.0pt;line-height:107%;font-family:"Times New Roman","serif"; color:black}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";}span.ad{text-decoration:underline;}p.oc{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-indent:-18.0pt;background:white}span.mv{font-size:10.0pt;line-height:107%;font-family:Symbol;color:black}span.mt{font-size:10.0pt;line-height:107%;font-family:"Times New Roman","serif"; color:#2D2D2D}span.ms{font-size:10.0pt;line-height:107%;font-family:"Times New Roman","serif"}p.od{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:18.75pt;text-align: justify;text-indent:-18.0pt}span.mr{font-size:10.0pt;line-height:107%; font-family:Symbol} span.mq{font-size:10.0pt;line-height: 107%;font-family:"Times New Roman","serif"}p.oe{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}span.mo{font-size:10.0pt;line-height: 107%;font-family:"Times New Roman","serif";color:black}p.of{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; margin-bottom: 18.75pt; text-align: justify}p.og{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:18.75pt;text-align: justify;text-indent:-18.0pt;background:white}span.ml{font-size:10.0pt; line-height:107%;font-family:Symbol;color:black}p.oh{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;text-indent:-18.0pt; background:white}span.mj{font-size:10.0pt;line-height:107%; font-family:"Times New Roman","serif"}p.oi{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;text-indent:-18.0pt; background:white}p.oj{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: justify} p.ok{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;text-indent:-18.0pt; background:white}p.ol{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify;background:white}p.om{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify}span.mf{color:red}table.on{margin-left:-10.8pt;border-collapse:collapse}td.lt{width:455.3pt;padding:0cm 5.4pt 0cm 5.4pt}p.oo{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify}table.op{border-collapse:collapse}td.mb{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.oq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify} td.ma{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.or{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify; text-autospace:ideograph-numeric ideograph-other}p.os{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.lx{color:windowtext}p.ot{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-right:-5.4pt;text-align:justify}p.ou{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;margin-left:7.1pt;text-align:justify}span.lq{font-size:14.0pt;font-family:"Times New Roman","serif"}br.lr{page-break-before:always}.ar{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 72.0pt 90.0pt;}div.ar{} p.ov{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-autospace: ideograph-numeric ideograph-other}span.lp{font-size:14.0pt}span.ln{font-size:12.0pt}p.ow{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}span.lm{font-family: "Times New Roman","serif"}span.ll{font-size:11.0pt}span.ox{color: black; font-size: 11.0pt; font-weight: bold}span.oy{font-size:11.0pt;color:black}p.oz{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.li{font-family:"Times New Roman","serif"} span.lh{font-size:11.0pt; color:black}p.pa{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold}p.pb{margin-right:0cm;margin-left:6.45pt;font-size:10.0pt;font-family:"Verdana","sans-serif";font-weight:bold;margin-left:0cm}span.lg{font-weight:normal}p.pc{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 1.0cm}h2.ld{text-align: left}table.pd{margin-left:-5.4pt;border-collapse:collapse}td.lc{width:186.15pt;padding:0cm 5.4pt 0cm 5.4pt}td.la{width:23.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.pe{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center} td.ky{width:53.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.pf{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: right}td.kw{width:1.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.pg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align: center}td.kv{width:48.7pt;padding:0cm 5.4pt 0cm 5.4pt}td.ku{width:3.3pt;padding:0cm 5.4pt 0cm 5.4pt}td.kt{width:51.05pt;padding:0cm 5.4pt 0cm 5.4pt}p.ph{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align: right}td.kr{width:53.7pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.kq{width:48.7pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.kp{width:51.05pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}tr.kh{height:3.55pt}td.ko{width:186.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.kn{width:23.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.km{width:53.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.kl{width:1.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.kk{width:48.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.kj{width:3.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.ki{width:51.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}tr.jz{height:12.6pt} td.kg{width:186.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.6pt}td.kf{width:23.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.6pt}td.ke{width:53.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.6pt}td.kd{width:1.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.6pt}td.kc{width:48.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.6pt}td.kb{width:3.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.6pt}td.ka{width:51.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.6pt}td.jy{width:53.7pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.jx{width:48.7pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.jw{width:51.05pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt} td.jv{width:53.7pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.ju{width:48.7pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.jt{width:51.05pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}tr.jl{height:15.45pt}td.js{width:186.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.45pt}td.jr{width:23.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.45pt}td.jq{width:53.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.45pt}td.jp{width:1.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.45pt}td.jo{width:48.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.45pt}td.jn{width:3.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.45pt} td.jm{width:51.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.45pt}td.jk{width:48.7pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.jj{width:53.7pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.ji{width:48.7pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.jh{width:51.05pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}tr.iz{height:13.05pt}td.jg{width:186.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:13.05pt}td.jf{width:23.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:13.05pt}td.je{width:53.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:13.05pt}td.jd{width:1.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:13.05pt} td.jc{width:48.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:13.05pt}td.jb{width:3.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:13.05pt}td.ja{width:51.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:13.05pt}span.ix{font-size:10.0pt;font-family:"Times New Roman","serif"}.as{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 72.0pt 90.0pt;}div.as{}p.pi{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 1.0cm; text-align: center}td.iv{width:205.15pt;padding:0cm 5.4pt 0cm 5.4pt}td.iu{width:56.6pt;padding:0cm 5.4pt 0cm 5.4pt}td.it{width:1.55pt;padding:0cm 5.4pt 0cm 5.4pt} td.is{width:53.3pt;padding:0cm 5.4pt 0cm 5.4pt}td.ir{width:4.85pt;padding:0cm 5.4pt 0cm 5.4pt}td.iq{width:56.6pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.ip{width:53.3pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.io{width:56.6pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.in{width:53.3pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.im{width:205.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.il{width:56.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.ik{width:1.55pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.ij{width:53.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt} td.ii{width:4.85pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.ih{width:56.6pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.ig{width:53.3pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.if{width:56.6pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.ie{width:53.3pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}.at{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 72.0pt 90.0pt;}div.at{}td.id{width:184.45pt;padding:0cm 5.4pt 0cm 5.4pt}td.ic{width:26.15pt;padding:0cm 5.4pt 0cm 5.4pt}td.ib{width:57.9pt;padding:0cm 5.4pt 0cm 5.4pt} td.ia{width:1.7pt;padding:0cm 5.4pt 0cm 5.4pt}td.hz{width:56.85pt;padding:0cm 5.4pt 0cm 5.4pt}td.hy{width:1.95pt;padding:0cm 5.4pt 0cm 5.4pt}td.hx{width:54.4pt;padding:0cm 5.4pt 0cm 5.4pt}td.hw{border:none;padding:0cm 0cm 0cm 0cm}td.hv{width:57.9pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.hu{width:56.85pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.ht{width:54.4pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.hs{width:57.9pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.hr{width:56.85pt;border:none;padding:0cm 5.4pt 0cm 5.4pt} td.hq{width:54.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.hp{width:56.85pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.ho{width:57.9pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.hn{width:54.4pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}tr.hf{height:10.45pt}td.hm{width:184.45pt;padding:0cm 5.4pt 0cm 5.4pt; height:10.45pt}td.hl{width:26.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:10.45pt}td.hk{width:57.9pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:10.45pt}td.hj{width:1.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:10.45pt}td.hi{width:56.85pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:10.45pt} td.hh{width:1.95pt;padding:0cm 5.4pt 0cm 5.4pt; height:10.45pt}td.hg{width:54.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:10.45pt}td.he{width:57.9pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.hd{width:56.85pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.hc{width:54.4pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}p.mn{font-weight: bold}span.hb{font-size:12.0pt;font-family:"Times New Roman","serif"}.au{size:841.9pt 595.3pt;margin:26.95pt 72.0pt 14.2pt 72.0pt;}div.au{}table.pj{width:739.15pt;margin-left:-5.4pt;border-collapse:collapse} td.ha{padding:0cm 5.4pt 0cm 5.4pt}td.gy{width:153.6pt;padding:0cm 5.4pt 0cm 5.4pt}span.gz{font-size:8.0pt}td.gx{width:38.1pt;padding:0cm 5.4pt 0cm 5.4pt}td.gw{width:52.8pt;padding:0cm 5.4pt 0cm 5.4pt}td.gv{width:26.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.gu{width:58.9pt;padding:0cm 5.4pt 0cm 5.4pt}td.gt{width:32.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.gs{width:46.1pt;padding:0cm 5.4pt 0cm 5.4pt}tr.gi{height:8.5pt} td.gr{padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.gq{width:153.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.gp{width:38.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.go{width:52.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.gn{width:1.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.gm{width:26.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.gl{width:58.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.gk{width:32.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.gj{width:46.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}p.pk{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";} span.gh{font-size: 8.0pt}p.pl{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";page-break-after: avoid; text-align: right}td.ge{width:38.1pt;padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.gd{width:52.8pt;padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.gc{width:1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.gb{width:26.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.ga{width:58.9pt;padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.fz{width:32.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.fy{width:46.1pt;padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}tr.fo{height:8.8pt} td.fx{padding:0cm 5.4pt 0cm 5.4pt;height:8.8pt}td.fw{width:153.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.8pt}td.fv{width:38.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.8pt}td.fu{width:52.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.8pt}td.ft{width:1.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.8pt}td.fs{width:26.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.8pt}td.fr{width:58.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.8pt}td.fq{width:32.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.8pt}td.fp{width:46.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.8pt}td.fn{width:38.1pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt} td.fm{width:52.8pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.fl{width:26.0pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.fk{border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.fj{width:58.9pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.fi{width:32.0pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.fh{width:46.1pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.fg{width:38.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.ff{width:52.8pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.fe{width:26.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.fd{border:none;padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt} td.fc{width:58.9pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.fb{width:32.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.fa{width:46.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}td.ez{width:38.1pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.ey{width:52.8pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.ex{width:26.0pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.ew{border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.ev{width:58.9pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.eu{width:32.0pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.et{width:46.1pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt} td.es{width:38.1pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.er{width:52.8pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.eq{width:26.0pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.ep{border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.eo{width:58.9pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.en{width:32.0pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}td.em{width:46.1pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.5pt}p.pm{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";page-break-after: avoid; text-align: center}.av{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 72.0pt 90.0pt;}div.av{} td.ej{width:165.8pt;padding:0cm 5.4pt 0cm 5.4pt}td.ei{width:29.75pt;padding:0cm 5.4pt 0cm 5.4pt}td.eh{width:53.9pt;padding:0cm 5.4pt 0cm 5.4pt}td.eg{width:3.35pt;padding:0cm 5.4pt 0cm 5.4pt}td.ef{width:57.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.ee{width:1.15pt;padding:0cm 5.4pt 0cm 5.4pt}td.ed{width:55.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.ec{width:53.9pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.eb{width:57.65pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.ea{width:55.65pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt} td.dz{width:53.9pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.dy{width:57.65pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.dx{width:55.65pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.dw{width:57.65pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.dv{width:53.9pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.du{width:55.65pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.dt{width:192.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.ds{width:3.05pt;padding:0cm 5.4pt 0cm 5.4pt}td.dr{width:53.9pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.dq{width:57.65pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.dp{width:55.65pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.do{width:201.6pt;padding:0cm 5.4pt 0cm 5.4pt}td.dn{width:58.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.dm{width:59.4pt;padding:0cm 5.4pt 0cm 5.4pt}td.dl{width:53.9pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.dk{width:57.65pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.dj{width:55.65pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.di{border:none}.aw{size:595.3pt 841.9pt;margin:72.0pt 74.55pt 72.0pt 61.5pt;}div.aw{} p.pn{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 28.7pt; punctuation-wrap: hanging; text-align: justify; text-indent: -27.0pt}p.po{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: justify}p.pp{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 28.7pt; punctuation-wrap: hanging; text-align: justify}p.pq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-left:28.7pt;text-align:justify;text-indent: -27.0pt;}p.pr{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-left:28.7pt;text-align:justify;punctuation-wrap: hanging}p.ps{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 1.0cm; text-align: justify; text-indent: -1.0cm}p.pt{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-left:28.0pt;text-align:justify;punctuation-wrap: hanging}p.pu{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-left:1.0cm;text-align:justify;text-indent: -1.0cm}table.pv{margin-left:27.0pt;border-collapse:collapse}td.cz{width:201.3pt;padding:0cm 5.4pt 0cm 5.4pt} td.cy{width:54.9pt;padding:0cm 5.4pt 0cm 5.4pt}td.cx{width:53.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.cw{width:3.2pt;padding:0cm 5.4pt 0cm 5.4pt}td.cv{width:51.45pt;padding:0cm 5.4pt 0cm 5.4pt}td.cu{width:54.9pt;border:none;border-bottom: double windowtext 2.25pt;padding:0cm 5.4pt 0cm 5.4pt}td.ct{width:53.0pt;border:none;border-bottom: double windowtext 2.25pt;padding:0cm 5.4pt 0cm 5.4pt}td.cs{width:51.45pt;border:none;border-bottom: double windowtext 2.25pt;padding:0cm 5.4pt 0cm 5.4pt}td.cr{width:54.9pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.cq{width:53.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.cp{width:51.45pt;border:none;padding:0cm 5.4pt 0cm 5.4pt} td.co{width:201.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.cn{width:54.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.cm{width:3.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.cl{width:53.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.ck{width:3.2pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.cj{width:51.45pt;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.ci{width:54.9pt;border:none;border-bottom: double windowtext 2.25pt;padding:0cm 5.4pt 0cm 5.4pt;height:3.55pt}td.ch{width:53.0pt;border:none;border-bottom: double windowtext 2.25pt;padding:0cm 5.4pt 0cm 5.4pt;height:3.55pt}td.cg{width:51.45pt;border:none;border-bottom: double windowtext 2.25pt;padding:0cm 5.4pt 0cm 5.4pt;height:3.55pt}td.cf{width:54.9pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt} td.ce{width:53.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.cd{width:51.45pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:3.55pt}td.cc{width:54.9pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.cb{width:53.0pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.ca{width:51.45pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}p.pw{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-left:32.2pt}tr.bt{page-break-inside:avoid;height:8.5pt}td.bw{width:21.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt}p.px{margin-top:16.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:16.0pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight:bold;margin-top:0cm;line-height:normal;page-break-after: auto}td.bu{width:421.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:8.5pt} p.py{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: -2.75pt}td.bs{width:21.3pt;padding:0cm 5.4pt 0cm 5.4pt}td.br{width:120.95pt;padding:0cm 5.4pt 0cm 5.4pt}td.bq{width:74.55pt;padding:0cm 5.4pt 0cm 5.4pt}td.bp{width:55.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.bo{width:57.35pt;padding:0cm 5.4pt 0cm 5.4pt}td.bn{width:2.05pt;padding:0cm 5.4pt 0cm 5.4pt}td.bm{width:54.1pt;padding:0cm 5.4pt 0cm 5.4pt}td.bl{width:206.3pt;padding:0cm 5.4pt 0cm 5.4pt}td.bk{width:194.2pt;padding:0cm 5.4pt 0cm 5.4pt} td.bj{width:1.3pt;padding:0cm 5.4pt 0cm 5.4pt}td.bi{width:133.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.bh{width:62.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.bg{width:55.5pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bf{width:57.35pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.be{width:54.1pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bd{width:55.5pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.bc{width:57.35pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.bb{width:54.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.ba{width:55.5pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt} td.az{width:57.35pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.ay{width:54.1pt;border:none;border-bottom:double windowtext 2.25pt; padding:0cm 5.4pt 0cm 5.4pt}p.pz{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-right:-2.75pt;text-align:justify} /**/
RNS Number : 0175O
Immupharma PLC
30 September 2019
 

RNS: RELEASE | 30 SEPTEMBER 2019

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

INTERIM RESULTS ANNOUNCEMENT
for the six months ended 30 June 2019

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2019 (the "Period").

 

Key Highlights (including post Period review)

 

Financials

·    Stable financial performance over the Period

o Cash balance of £2.3 million as at 30 June 2019 (31 December 2018:  £4.9 million)

o Derivative financial asset of £1.9 million as at 30 June 2019 (31 December 2018: nil)

o Loss for the period of £3.9 million (30 June 2018:  £4.1 million)

o Research and development expenses of £1.4 million (30 June 2018: £2.5 million)

o Basic and diluted loss per share of 2.80p (30 June 2018: 2.94p)

o Subscription agreement with Lanstead Capital Investors LP raising approximately £2.66 million

§ Lanstead retains a holding of over 16% in ImmuPharma

 

LupuzorTM
 

·      Open label extension study - Following the completion of LupuzorTM's Phase III clinical trial in January 2019, ImmuPharma undertook an open label extension study.  Analysis of results from Lupuzor's™ 'extension' open label study were announced on 28 June 2019

o 62 eligible patients enrolled throughout the US and Europe completing a 24-week treatment period

o Primary endpoint successfully achieved confirming the safety profile of Lupuzor™

o No 'serious adverse events' related to Lupuzor™ reported

o Insights into the Phase III data allow an optimised Lupuzor™ phase III design to progress

·      Exploration within the P140 platform for different auto-immune indications outside of lupus continues

 

Other program developments

·      Within our two further platforms, Ureka Sarl (Peptide) and Elro Pharma (Nucant) , ImmuPharma continues to explore options to license, divest or 'spin-off' the technologies to unlock future potential and enhance value to shareholders

·      The peer reviewed research journal 'Nature Communications' paper published on the proprietary technology Urelix™ from Ureka - Superior GLP-1 analogues pave way for peptide types across many therapy areas

·      Negotiations with Incanthera Limited on the Nucant cancer programme and broader collaboration discussions terminated  - ImmuPharma retains a 15% shareholding in Incanthera

Industry reports

·      The Life Sciences Division published an initiation research note on ImmuPharma in May 2019 

Commenting on the statement and outlook Tim McCarthy, Chairman, said: "With further analysis gained from our Phase III results, together with our extension study successfully meeting its endpoint confirming its safety profile, we are focused on progressing LupuzorTM into a further Phase III trial. Our plans to create further shareholder value within our Peptide Platform (Ureka) and Nucant (Elro Pharma) continue. We look forward to reporting on these developments. We would also like to take this opportunity to thank our shareholders, scientific advisors, corporate collaborators and the CNRS."

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

+ 44 (0) 207 152 4080

Tim McCarthy, Chairman

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

 

ImmuPharma plc

Chairman's Statement

 

INTERIM HIGHLIGHTS

 

The first half of 2019 saw a number of developments for ImmuPharma including the announcement of results for the open label extension study for LupuzorTM

 

On 26 June 2019, the Company announced that it entered into a subscription agreement with Lanstead Capital Investors LP ('Lanstead'), an institutional investor, together with a sharing agreement, raising approximately £2.66 million.

 

LupuzorTM Phase III open label extension results and next steps

 

Following on from LupuzorTM's pivotal Phase III trial that was completed in 2018, in June 2019, the Company announced the results of LupuzorTM's open label extension study.  There were 62 patients enrolled in the study throughout the US and Europe who completed a 24-week treatment period.  The primary endpoint was successfully achieved confirming the safety profile of LupuzorTM with no serious adverse events reported.  Insights provided by the study allow an optimised LupuzorTM phase III design to progress.

 

The open label extension study followed the pivotal Phase III clinical trial for LupuzorTM, the results of which were announced in April 2018.  The Phase III trial was a double-blind, randomised, placebo-controlled trial. The study involved patients being dosed for one year, receiving 0.2mg once per month subcutaneously. 293 patients were screened illustrating the demand from physicians for a new, safe and effective treatment for lupus. Of these, the required 202 patients were successfully recruited and randomised (dosed).  Patients participated in the trial in 7 countries across 28 sites. 

 

The clinical trial was undertaken primarily by Simbec-Orion, an international clinical research organisation, who specialises in rare and orphan conditions and has previous direct experience in lupus trials. This was a pivotal study designed to demonstrate the safety and efficacy of Lupuzor.

 

Lupuzor™ demonstrated a superior response rate over placebo (52.5% vs 44.6% "responders") in the primary analysis on the Full Analysis Set of all 202 patients. However, due to the high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial's primary end point was not met.

 

Across the whole study population, in those patients who had anti-dsDNA autoantibodies, LupuzorTM demonstrated a superior response rate over placebo (61.5% vs 47.3%, p = 0.0967).  Although these results were not statistically significant, further data analysis demonstrated that in the Europe cohort (130 patients) LupuzorTM plus standard of care showed statistically significant reductions in disease activity compared to placebo plus standard of care in 79 patients who were anti-dsDNA autoantibody positive (71.1% vs 48.8%, p = 0.0218). 

 

The study confirmed the outstanding safety profile of LupuzorTM, with no serious adverse events reported. 

 

Scientific literature indicates that approximately 60% - 70% of patients diagnosed for lupus are anti-dsDNA autoantibody positive.  These proportions were seen in the Europe cohort (60.8% of patients) and could therefore be considered as representative of the overall lupus population.

 

In those patients who were anti-dsDNA autoantibody negative, there was almost no difference in disease activity reduction between the active group and the comparator group. Anti-dsDNA autoantibodies are a recognised biomarker for Systemic Lupus Erythematosus. 

 

This finding indicates that the activity of LupuzorTM could be correlated with the presence of anti-dsDNA autoantibodies in lupus patients.  ImmuPharma believes that predictive biomarkers, such as anti-dsDNA autoantibodies, could allow identification of patients that are more likely to respond positively to treatment with LupuzorTM

 

LupuzorTM next steps

 

ImmuPharma believes there are still a number of pathways to market for LupuzorTM and, as such, continues to consult with regulatory advisors on these activities.  The prime objective of any strategy would be to maximise shareholder return.

 

ImmuPharma also maintains a focus on exploring opportunities within the P140 platform for different auto-immune indications outside of lupus, based on encouraging pre-clinical data. 

 

ImmuPharma has also taken steps toward the implementation of a Managed Access Program for LupuzorTM.  Recognising that lupus is a disease with significant unmet medical need and given the advanced level of clinical trial investigation completed, ImmuPharma would like to meet demand for access to LupuzorTM through clinicians.  These plans have been postponed while alternative options are explored.

 

Ureka 

 

The Group's subsidiary Ureka sarl ('Ureka') has been developing lead compounds from its novel and patented peptide technology platform UrelixTM.  Ureka is based at the Institut Europeen de Chimnie et Biologie (IECB) in Bordeaux, France which is under the joint authority of the CNRS, Inserm and the University of Bordeaux.

 

UrelixTM is focusing on oligourea foldamers as a tool to improve the pharmaceutical properties of peptides.  One of the first focus areas of Ureka has been GLP-1 analogues for the treatment of Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) as proof of concept for its technology.  In February 2019, the peer reviewed scientific research journal 'Nature Communications' published a paper on Ureka's technology.

 

As announced in May 2019, the Company is pursuing plans to combine the Ureka and Elro subsidiaries. The intention is to maximise value from the combined entity whilst retaining an interest in any future commercial success. 

 

Nucant Platform

 

A number of options have been under review to develop the Company's Nucant cancer programme.

 

In September 2018, the Company signed a Heads of Terms agreement with Incanthera ("Incanthera") regarding a potential collaboration on the Nucant program.  At the same time, ImmuPharma invested £2 million to purchase 363,637 shares at £5.50 per share in Incanthera and received warrants for a further 363,637 shares at £5.50.  In May 2019, following a period of wide-ranging discussions, ImmuPharma announced that discussions regarding a clinical development collaboration with Incanthera Limited had ceased.  The Company continues to be supportive of Incanthera and retains a 15% shareholding. 

 

Following a review of options for progressing this program, ImmuPharma is pursuing a strategy to combine Elro with the Group's Ureka subsidiary. 

 

Lanstead Capital Subscription

 

On 26 June 2019, the Company announced that it entered into a subscription agreement with Lanstead Capital Investors LP ("Lanstead"), an institutional investor, together with a related sharing agreement ("Sharing Agreement"), raising approximately £2.66 million.  Lanstead subscribed for 26,565,200 new ordinary shares of 10 pence each in the Company at an issue price of 10 pence per Subscription Share to raise gross proceeds of approximately £2.66 million, representing approximately 19% of the Company's existing share capital (the "Subscription").  The subscription represents a further supportive investment in the Company by Lanstead following the £4.43 million investment in February 2016, from which the Company ultimately received just over £5.0 million from Lanstead including the additional funds received through the Sharing Agreement over time.

 

The £2.66 million gross proceeds of the Subscription were pledged by the Company pursuant to the Sharing Agreement with Lanstead.  The Sharing Agreement, details of which are contained in the Notes to the Interim Accounts, entitles the Company to receive back those proceeds on a pro rata monthly basis over a period of 24 months, structured to commence two months following the admission to AIM of the Subscription Shares, subject to adjustment upwards or downwards each month depending on the Company's share price at the time. The Sharing Agreement provides the opportunity for the Company to benefit from positive future share price performance.

 

The Company also agreed to issue Lanstead 1,328,290 ordinary shares in connection with entering into the Sharing Agreement.

 

Financial Review

 

ImmuPharma's cash balance at 30 June 2019 was £2.3 million (£4.9 million at 31 December 2018, £9.0 million at 30 June 2018).  As a result of the Lanstead Subscription and Sharing Agreement, the Company had a derivative financial asset of £1.9 million at 30 June 2019 (30 June 2018: £nil). Basic and diluted loss per share were 2.80p and 2.80p respectively (30 June 2018: 2.94p and 2.94p).  In line with the Company's current policy, no interim dividend is proposed.

 

Operating loss for the Period was £3.3 million (£4.1 million for the six months ended 30 June 2018).  Research and development expenditure in the Period was £1.4 million (£2.5 million for the six months ended 30 June 2018) reflecting primarily the expenditure related to the LupuzorTM Phase III clinical trial. Administrative expenses were £0.9 million during the Period (£1.0 million for the six months ended 30 June 2018).  The share based expense was £1.0 million (£0.8 million for the six months ended 30 June 2018).  Finance costs for the Period were £842k (£29k for the six months ended 30 June 2018). This primarily arose due to the calculation of fair value of the Lanstead Sharing Agreement based on the Company's share price at 30 June 2019.  The restatement to fair value will be calculated at the end of each accounting period during the course of the Sharing Agreement and will vary according to the Company's share price performance.

 

Given the stage of ImmuPharma's development, the fact that losses have continued to be made is to be expected since there is minimal revenue and business activity is concerned with significant investment in the form of clinical development expenditure, in addition to maintaining the infrastructure of the Company.

 

Current Activities and Outlook

 

The Board has been focused on delivering a business strategy which provides the optimum route forward for ImmuPharma and its shareholders, based on its current assets, resources and knowhow.  In the medium term, we remain focussed on achieving the full regulatory approval of LupuzorTM which we believe has the potential to be a ground breaking drug for lupus patients with blockbuster potential in commercial terms. 

 

Our Ureka subsidiary and Nucant programme have been part of our portfolio for a number of years.  We are equally excited by the potential of both.  We believe the strategy we are pursuing with the merger of Ureka and Elro will create enhanced value for shareholders going forward.

 

The Board would like to thank its shareholders for their support as well as its staff, corporate and scientific advisers including Simbec-Orion and the CNRS (Centre Nationale de la Recherche Scientifique) for their continued collaboration.

 

 

 

 

Tim McCarthy                                  

Chairman

           

 

 

 

 

 


ImmuPharma plc

 

CONSOLIDATED INCOME STATEMENT

FOR THE PERIOD ENDED 30 JUNE 2019

 

 

 

 

 

Note

Unaudited

6 months ended

30 June 2019

 

Audited

Year

 ended 31 December

2018

 

Unaudited

6 months ended

30 June 2018

 

 

£

 

£

 

£

Continuing operations

 

 

 

 

 

 

Revenue

1

          11,737

 

81,281

 

       73,392

Research and development expenses

 

(1,362,933)

 

(4,697,284)

 

(2,455,490)

Administrative expenses

 

(931,761)

 

(1,660,408)

 

(992,085)

Share based expense

 

(1,005,101)

 

(1,803,769)

 

(775,135)

 

 

 

 

 

 

 

Operating loss

 

(3,288,058)

 

(8,080,180)

 

(4,149,318)

 

 

 

 

 

 

 

Finance costs

4

(842,293)

 

(4,783)

 

(29,425)

Finance income

 

          4,257

 

129,808

 

6,077

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before taxation

 

(4,126,094)

 

(7,955,155)

 

(4,172,666)

 

 

 

 

 

 

Tax

 

225,250

 

748,606

 

      110,237

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the period

 

(3,900,844)

 

(7,206,549)

 

(4,062,429)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to:

 

 

 

 

 

 

Equity holders of the parent company

 

(3,900,844)

 

(7,206,549)

 

(4,062,429)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per ordinary share

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

2

(2.80)p

 

(5.19)p

 

(2.94)p

 

 

 

 

 

 

 

 

 

 

ImmuPharma plc

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 JUNE 2019

 

 

 

Unaudited

6 months ended

30 June

 2019

 

Audited

Year

 ended 31 December

2018

 

Unaudited

6 months ended

30 June

 2018

 

£

 

£

 

£

 

 

 

 

 

 

Loss for the financial period

(3,900,844)

 

(7,206,549)

 

(4,062,429)

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income

 

 

 

 

 

Items that may be reclassified subsequently to profit or loss:

 

 

 

 

 

 

Exchange differences on translation of foreign operations


75,594

 


(88,256)

 


29,459

 

 

 

 

 

 

 

 

 

 

 

 

Total items that may be reclassified subsequently to profit or loss

75,594

 

(88,256)

 

29,459

 

 

 

 

 

 

Other comprehensive income/(loss) for the period

 

75,594

 


(88,256)

 


29,459

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive loss for the period

(3,825,250)

 

(7,294,805)

 

(4,032,970)

 

 

 

 

 

 

 

 

 

 

 

ImmuPharma plc

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2019

 

 

Note

Unaudited

30 June

2019

 

Audited

31 December

2018

 

Unaudited

30 June 2018

 

 

 

£

 

£

 

£

 

Non-current assets

 

 

 

 

 

 

 

Intangible assets

 

500,077

 

483,039

 

481,667

 

Property, plant and equipment

Financial asset

 

133,714

2,000,000

 

164,661

2,000,000

 

120,675

-

 

Derivative financial asset

4

1,014,592

 

-

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total non-current assets

 

3,648,383

 

2,647,700

 

602,342

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Trade and other receivables

 

257,216

 

       331,487

 

1,174,720

 

Cash and cash equivalents

 

2,258,951

 

4,911,448

 

9,015,630

 

Current tax asset

 

978,921

 

767,121

 

-

 

Derivative financial asset

 

857,298

 

-

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current assets

 

4,352,386

 

6,010,056

 

10,190,350

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Financial liabilities - borrowings

 

(96,961)

 

(98,340)

 

(138,214)

 

Trade and other payables

 

(444,398)

 

(913,907)

 

(737,035)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

(541,359)

 

(1,012,247)

 

(875,249)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net current assets

 

3,811,027

 

4,997,809

 

9,315,101

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

Financial liabilities - borrowings

 

-

 

(22,470)

 

(61,209)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net assets

 

7,459,410

 

7,623,039

 

9,856,234

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

Ordinary shares

 

13,946,744

 

13,946,744

 

13,946,744

 

Share premium

 

27,320,145

 

27,320,145

 

27,320,143

 

Merger reserve

 

106,148

 

106,148

 

106,148

 

Other reserves

 

2,745,217

 

(991,998)

 

(1,902,921)

 

Retained earnings

 

(36,658,844)

 

(32,758,000)

 

(29,613,880)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total equity

 

7,459,410

 

7,623,039

 

9,856,234

 

 

 

 

 

 

 

 

 

 

 

ImmuPharma plc

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 30 JUNE 2019

 

 

 

Share capital

 

Share premium

 

 

 

 

 

 

Merger

reserve

 

 

 

 

Other reserves -

Acquisition

reserve

 

 

 

 

Other

reserves -

Translation

Reserve

 

Other reserves -

Equity shares

to be issued

 

Other reserves-

New equity shares

to be issued

 

 

 

 

 

 

 

Retained

Earnings

 

Total

equity

 

 

£

 

£

 

£

 

£

 

£

 

£

 

£

 

£

 

£

 

At 1 January 2018

 

13,252,299

 

18,728,519

 

106,148

 

(3,541,203)

 

(1,701,241)

 

2,281,427

 

-

 

(25,551,451)

 

3,574,498

 

Loss for the financial period

-

 

-

 

-

 

-

 

-

 

-

 

-

 

(4,062,429)

 

(4,062,429)

 

Exchange differences on translation

of foreign operations

-

 

-

 

-

 

-

 

29,459

 

-

 

-

 

-

 

29,459

 

New issue of equity capital

694,445

 

9,305,555

 

-

 

-

 

-

 

-

 

-

 

-

 

10,000,000

 

Cost of new issue of equity capital

-

 

(713,931)

 

-

 

-

 

-

 

-

 

-

 

-

 

(713,931)

 

Share based payments

-

 

-

 

-

 

-

 

-

 

1,028,637

 

-

 

-

 

1,028,637

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 30 June 2018

13,946,744

 

27,320,143

 

106,148

 

(3,541,203)

 

(1,671,782)

 

3,310,064

 

-

 

(29,613,880)

 

9,856,234

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 1 January 2018

13,252,299

 

18,728,519

 

106,148

 

(3,541,203)

 

(1,701,241)

 

2,281,427

 

-

 

(25,551,451)

 

3,574,498

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the financial year

-

 

-

 

-

 

-

 

                    -

 

-

 

-

 

(7,206,549)

 

(7,206,549)

 

Exchange differences on translation

of foreign operations

-

 

-

 

-

 

-

 

                         (88,256)

 

-

 

-

 

-

 

(88,256)

 

Transactions with owners:

Share based payments

-

 

-

 

-

 

-

 

-

 

2,057,275

 

-

 

-

 

2,057,275

 

New issue of equity capital

694,445

 

9,305,555

 

-

 

-

 

-

 

-

 

-

 

-

 

(10,000,000)

 

Cost of new issue of equity capital

-

 

(713,929)

 

-

 

-

 

-

 

-

 

-

 

-

 

(713,929)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 31 December 2018 & 1 January 2019

13,946,744

 

27,320,145

 

106,148

 

(3,541,203)

 

(1,789,497)

 

4,338,702

 

-

 

(32,758,000)

 

7,623,039

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the financial period

-

 

-

 

-

 

-

 

-

 

-

 

-

 

(3,900,844)

 

(3,900,844)

 

Exchange differences on translation of foreign operations

 

-

 

 

-

 

 

-

 

 

-

 

 

75,594

 

 

-

 

 

-

 

 

-

 

                      75,594

 

Transactions with owners:

Share based payments

-

 

-

 

-

 

-

 

-

 

1,005,101

 

-

 

-

 

        1,005,101

 

New shares to be issued

-

 

-

 

-

 

-

 

-

 

-

 

2,656,520

 

-

 

2,656,520

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 30 June 2019

13,946,744

 

27,320,145

 

106,148

 

(3,541,203)

 

(1,713,903)

 

5,343,803

 

2,656,520

 

(36,658,844)

 

7,549,410

 

Attributable to:-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity holders of the parent company

13,946,744

 

27,320,145

 

106,148

 

(3,541,203)

 

(1,713,903)

 

5,343,803

 

2,656,520

 

(36,658,844)

 

7,549,410

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ImmuPharma plc

 

CONSOLIDATED STATEMENT OF CASHFLOWS

FOR THE PERIOD ENDED 30 JUNE 2019

 

 

Note

Unaudited

6 months ended

30 June 2019

 

Audited

Year

 ended

31 December

2018

 

Unaudited

6 months ended

30 June

2018

 

 

 

£

 

£

 

£

 

Cash flows from operating activities

 

 

 

 

 

 

 

Cash used in operations

3

 (2,687,173)

 

(5,606,138)

 

(3,150,500)

 

Tax

 

                 -

 

889,787

 

213,724

 

Interest paid

 

         (1,581)

 

(4,783)

 

(2,423)

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

(2,688,754)

 

 

(4,721,134)

 

(2,939,199)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

         (4,502)

 

 

(102,880)

 

(7,946)

 

Purchase of investments

 

               -

 

(2,000,000)

 

-

 

Interest received

 

         4,257

 

12,491

 

6,077

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

           (245)

 

(2,090,389)

 

(1,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

 

 

(Decrease)/increase in bank overdraft

 

            (110)

 

(72)

 

             (122)

 

Loan repayments

 

      (23,739)

 

(138,809)

 

(58,615)

 

Gross proceeds from issue of new share capital

 

                -

 

10,000,000

 

10,000,000

 

Share capital issue costs

 

                  -

 

(713,929)

 

(713,931)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash generated from financing activities

 

(23,849)

 

9,147,190

 

9,227,332

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

 

(2,712,848)

 

2,335,667

 

6,286,264

 

Cash and cash equivalents at start of period

 

4,911,448

 

2,729,468

 

2,729,468

 

 

Effects of exchange rates on cash and

cash equivalents

 

60,351

 

 

(153,687)

 

 

(102)

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

 

2,258,951

 

4,911,448

 

 

9,015,630

 

 

 

 

 

 

 

 

 

                 

 

 

 

ImmuPharma plc

 

NOTES TO THE CONSOLIDATED INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE 2019

 

1          ACCOUNTING POLICIES

 

Basis of preparation

 

The interim financial information in this report has been prepared using accounting policies consistent with IFRS as adopted by the European Union. IFRS is subject to amendment and interpretation by the International Accounting Standards Board (IASB) and the IFRS Interpretations Committee and there is an ongoing process of review and endorsement by the European Commission.  The financial information has been prepared on the basis of IFRS to be adopted by the European Union and applicable as at 31 December 2019. The Group has chosen not to adopt IAS 34 "Interim Financial Statements" in preparing the interim financial information.

 

The accounting policies applied are consistent with those that were applied to the financial statements for the year ending 31 December 2018, with the exception of IFRS 16 "Leases" which is a new standard applicable for the year ending 31 December 2019. The adoption of the new standard did not have a material impact on the interim financial information set out in this report.

 

             Non-Statutory accounts

 

The financial information set out in this interim report does not constitute the Group's statutory accounts, within the meaning of Section 434 of the Companies Act 2006. The statutory accounts for the year ended 31 December 2018 have been filed with Registrar of Companies. The auditors reported on those accounts; their report was unqualified, did not contain a statement under either Section 498 (2) or Section 498 (3) of the Companies Act 2006 but did include an emphasis of matter paragraph relating to the uncertainty over the fair value of the investment in Incanthera Limited. The financial information for the 6 months ended 30 June 2019 and 30 June 2018 is unaudited.

 

             Copies of this statement will be available on the Company's website - www.immupharma.com.

 

 

 

 

 

 

ImmuPharma plc

 

NOTES TO THE CONSOLIDATED INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE 2019

(Continued)

 

 

2              LOSS PER SHARE

               

 

 

Unaudited
6 months ended 30 June 2019

 

Audited

Year ended 31 December

2018

 

Unaudited
6 months ended 30 June 2018

 

£

 

£

 

£

 

 

 

 

 

 

Loss

 

 

 

 

 

Loss for the purposes of basic and diluted loss per share being net loss attributable to equity shareholders

(3,900,844)

 



(7,206,549)

 

(4,062,429)

 

 

 

 

 

 

 

 

 

 

 

 

Number of shares

 

 

 

 

 

Weighted average number of ordinary shares for the purposes of basic loss per share

139,467,430

 

138,839,576

 

138,201,316

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic loss per share

(2.80)p

 

(5.19)p

 

 

 

 

(2.94)p

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted loss per share

(2.80)p

 

(5.19)p

 

(2.94)p

 

 

 

 

 

 

 

 

 

 

 

 

 

There is no difference between basic loss per share and diluted loss per share as the share options and warrants are anti-dilutive.

 

 

 

 

         

ImmuPharma plc

 

NOTES TO THE CONSOLIDATED INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE 2019

 

(Continued)

 

3

CASH USED IN OPERATIONS

 

 

 

 

Unaudited

6 months ended

30 June 2019

 

Audited

Year ended 31 December 2018

 

Unaudited

6 months

ended

30 June 2018

 

 

 

 

£

 

£

 

£

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

(3,288,058)

 

(8,080,180)

 

  (4,149,318)

 

 

Depreciation & amortisation

50,946

 

133,080

 

          81,424

 

Share based payments

1,005,101

 

2,057,275

 

     1,028,637

 

Decrease in trade & other receivables

 

72,517

 

404,725

 

358,921

 

 

(Decrease)/increase in trade & other payables

 

(469,509)

 

15,151

 

(189,656)

 

 

(Decrease)/increase in provisions

 

-

 

(253,506)

 

(253,506)

 

 

Gain/(loss) on foreign exchange

 

(58,170)

 

117,317

 

(27,002)

 

 

 

 

 

 

 

 

 

 

 

 

Cash used in operations

 

 

(2,687,173)

 

 

(5,606,138)

 

 

(3,150,500)

 

 

 

 

 

 

 

 

 

 

                       

 

 

 

 

 

 

 

 

ImmuPharma plc

 

NOTES TO THE CONSOLIDATED INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE 2019

 

(Continued)

 

4

 

 

 

DERIVATIVE FINANCIAL ASSET

 

In June 2019, as part of a placing that raised, in aggregate, £2.66 million (before expenses) from new and existing shareholders, the Company issued 26,565,200 new ordinary shares to Lanstead Capital LP ('Lanstead') at a price of 10p per share for £2.66 million. All of the shares with full voting rights were allotted to Lanstead on 2 July 2019. The Company simultaneously entered into a Sharing Agreement with Lanstead for 100% of these shares with a reference price of 13.33p per share. The Sharing Agreement is for a 24 month period. The actual consideration is variable depending upon the Company's share price. The Sharing Agreement is treated as a derivative financial asset and valued at fair value through the income statement with reference to the Company's share price as at the end of the accounting period.

 

On 2 July 2019, the Company also issued, in aggregate, a further 1,328,290 new ordinary shares to Lanstead as a value payment in connection with the Share Subscription and the Sharing Agreement.

 

At the end of the accounting period the amount receivable is restated to fair value based upon the share price of the Company at that date. Any change in the fair value of the derivative financial asset is reflected in the income statement. As at 30 June 2019, the Company completed a calculation of fair value of the derivative financial asset that resulted in a finance loss of £785k which was recorded in the income statement.  The restatement to fair value will be calculated at the end of each accounting period during the course of the Sharing Agreement and will vary according to the Company's share price performance.

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IR CKODPQBKDOCB

Quick facts: ImmuPharma PLC

Price: 8.405

Market: AIM
Market Cap: £14.07 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

on 11/9/19